Lhrh Agonist and Antagonist for Metastatic Prostate Cancer

LHRH agonists and antagonists are crucial in managing metastatic prostate cancer. These agents target the hypothalamus and pituitary gland, suppressing the production of luteinizing hormone-releasing hormone (LHRH). By doing so, they reduce testosterone levels, a key driver of prostate cancer growth. LHRH agonists like leuprolide and goserelin are widely used as first-line treatments, while newer [...]